Darren McGuire, MD, MHSc

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Boehringer Ingelheim
    Topic:
    Consultant
    Date added:
    Date updated:
    06/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    AstraZeneca
    Topic:
    Trial Leadership; Consultant
    Date added:
    Date updated:
    06/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Pfizer
    Topic:
    Trial leadership; Consultancy
    Date added:
    Date updated:
    06/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Novo Nordisk
    Topic:
    Trial Leadership; Consultant
    Date added:
    Date updated:
    06/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Esperion
    Topic:
    Trial Leadership
    Date added:
    Date updated:
    06/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Lilly USA
    Topic:
    Trial Leadership; Consultant
    Date added:
    Date updated:
    06/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Applied Therapeutics
    Topic:
    Consultant
    Date added:
    Date updated:
    06/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Afimmune
    Topic:
    Consultant
    Date added:
    Date updated:
    06/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    CSL Behring
    Topic:
    Trial leadership; Consultant
    Date added:
    12/12/2021
    Date updated:
    06/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Bayer
    Topic:
    Consultant
    Date added:
    12/12/2021
    Date updated:
    06/06/2025

Pages

Return to Cardiology Clinical Conference: "From Xenotransplantation to Reprogramming: Towards Curative Therapies for Heart Failure" & "Obesity Medications and Cardiovascular Risk: Increasing Weight of the Evidence" (092723)

 

**Disclaimer**

This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.